Karista
VC Fund
Paris, France
Karista is an early-stage venture capital firm created in 2001. We funded 90+ companies over the past two decades and support tomorrow’s game changers in the field of Health, Digital, Tech, and NewSpace. We have always worked to provide more than cash and partnered with entrepreneurs whom we share a common vision with.
- Total investments:
- 159
- Last investment:
- Lead investor:
- 18%
- Fund size:
- $44M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Karista invests in
Stages Karista invests in
Countries Karista invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Seed
- $768k–$6.2M
- Series A
- $1.4M–$23M
- Series B
- $2.5M–$33M
Investment Focus
Industry
- Software 27 (17%)
- Biotechnology 21 (13%)
- Health Care 18 (11%)
- Information Technology 16 (10%)
- Medical 12 (8%)
Stage
- Seed 62 (39%)
- Series A 29 (18%)
- Series B 19 (12%)
- Venture - Series Unknown 12 (8%)
- Funding Round 7 (4%)
Country
- France 81 (51%)
- United States 7 (4%)
- Finland 2 (1%)
- Germany 2 (1%)
- Switzerland 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Agathe Testu
Secretary General - RCCI
|
Secretary General - RCCI | Total investments: 0 | Find email | |
Baudouin Hue
Partner
|
Partner | Total investments: 5 | Find email | |
Benjamin Zerbib
Investment Director
|
Investment Director | Total investments: 5 | Find email | |
Catherine Boule
Managing Partner
|
Managing Partner | Total investments: 19 | Find email | |
Elodie Feraille
Management Assistant
|
Management Assistant | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Waiv
|
Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer.They use AI to identify new drug candidates, de-risk and accelerate clinical trials and builddiagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016.Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi. | $33M / Venture - Series Unknown / Mar 12, 2026 | |
constellr
|
Constellr creates imaging technology for the agriculture industry to evaluate soil health, vegetation, and industrial monitoring, using proprietary space infrastructure. Constellr supports food security by enabling high-precision smart farming services across the globe. The company specializes in tackling climate change with accountability andmonitoring data for multiple markets. | $44M / Series A / Feb 10, 2026 | |
Leanspace
|
Today, space organizations need to build and manage increasingly complex ground software infrastructures: to design, integrate and operate their assets. To do so, they can rely on off-the-shelf systems (COTS) but lose control over their tools, or build everything from scratch which is slow and consumes lots of resources.Leanspace brings a new wayto build space software. We provide all the generic functions, easily consumable as-a-service, via APIs. The platform enables organizations to build all their systems in-house, but only developing the functionalities they need. This drastically reduces time & costs, keeps them in control, and boosts competitiveness.Leanspace-powered systems are integrated, collaborative and digital. Don’t reinvent the wheel, transform your business! | $11.6M / Series A / Nov 17, 2025 | |
TiHive Technologies
|
TiHive Technologies built an innovative interconnectable and scalable imaging and sensing system, where many devices operate together at high speeds forming hives of intelligent see-through cameras. | $9.4M / Oct 02, 2025 | |
Look Up Space
|
Look Up Space provides Space Safety and Security data & services of unprecedented quality, with a dedicated, sovereign and secure sensor network and state-of-the-art data processing capabilities. | $27.6M / Series A / Jun 11, 2025 | |
Sitowie
|
Sitowie develops SaaS technology and tools to understand the degradation of buildings. | $3.1M / Seed / Apr 30, 2025 | |
SamanTree Medical
|
SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room. | $6M / Series B / Apr 03, 2025 | |
BforeAI
|
BforeAI focuses in predictive attack intelligence and Digital Risk Protection Services (DRPS). Empowered by PreCrime™ technology featuring behavioral AI, we aim to transform cyber defense from reactive to proactive. Our solutions encompass automated threat intelligence, brand protection, adversary disruption, and domain takedowns. Recognized byGartner in five reports and honored with awards like the FinTech Innovation Lab New York, Bfore.AI offers the industry's swiftest, most precise automated defense against online fraud. | $10M / Series B / Dec 15, 2024 | |
|
Brightflow
|
Brightflow operates as a medical device startup. | $18.2M / Series A / Sep 10, 2024 | |
Deemea
|
Deemea is a collaborative AI platform that connects and provides services for the analysis of medical data for physicians. It uses its expertise in clinical research, data science, and software development to help healthcare professionals. | $4.3M / Seed / Jun 05, 2024 | |
| See all 159 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Karista invest in?
Karista invests primarily in Software, Biotechnology and Health Care startups, most often at Seed and Series A stage. Most of the 159 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Karista's check size?
Karista typically joins rounds of $768k–$6.2M at Seed, $1.4M–$23M at Series A and $2.5M–$33M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Karista participates in.
How do I contact Karista?
Public channels for Karista include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Karista?
The team at Karista includes Agathe Testu (Secretary General - RCCI), Baudouin Hue (Partner) and Benjamin Zerbib (Investment Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
